Reliance on third-party software vendors differentiates INC Research from its technology-investing peers but will not be a disadvantage, according to a Jefferies analyst.
As larger partnerships between CROs and sponsors come to maturity, a new survey found that “a much greater proportion of CRO revenue growth” will come from small and medium-sized pharma and biotech sponsor deals.
Covance has sold its high-complexity genomics laboratory to LabCorp as part of what an analyst says is decisive action to shed underperforming assets in its Early Development business.
New research suggests that – in general - strategic partnerships are working but CROs still need to improve on sponsors’ ‘high priority’ objectives or risk losing deals.